Hagop Kantarjian/mdanderson.org
Mar 10, 2024, 20:49
Hagop Kantarjian: In this phase 2 study, a convenient, fully-oral regimen was effective and safe in an older/unfit population with acute myeloid leukemia
Hagop Kantarjian, a Professor and Chair of the Department of Leukemia at The University of Texas MD Anderson Cancer Center, recently posted on X:
“In this phase 2 study, a convenient, fully-oral regimen was effective and safe in an older/unfit population with acute myeloid leukemia. ”
Source: Hagop Kantarjian/X
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Aug 8, 2025, 05:47
Aug 8, 2025, 05:01
Aug 7, 2025, 21:48
Aug 7, 2025, 21:02
Aug 7, 2025, 20:53